Back

Medvarsity Technologies Private Limited

  • Biosimilar Pharmaceuticals
  • Inflammatory Bowel Diseases

Improving outcomes in IBD with early effective therapy & biosimilars

This educational activity aims to update healthcare professionals on current, evidence-based practices regarding Improving outcomes in IBD with early effective therapy & biosimilars, strengthening clinical competence and improving patient care.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.75 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • Credit · Up to 0.75 credits
  • Released
    Jul 1, 2026
  • Last day to claim credit
    Jul 1, 2027 9 months left